Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-girentuximab PET Imaging in ccRCC
NCT07077083Phase 2Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma (ccRCC), sponsored by Massachusetts General Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
89Zr-DFO-girentuximab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07077083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077083.